Evidence map›Paper›PMID 29656758›Full record

ArticleLung cancer (Amsterdam, Netherlands)2018

Feasibility of endobronchial ultrasound transbronchial needle aspiration for massively parallel next-generation sequencing in thoracic cancer patients.

Simon R Turner, Darren Buonocore, Patrice Desmeules, Natasha Rekhtman, Snjezana Dogan, Oscar Lin, Maria E Arcila, David R Jones, James Huang

Abstract read
In one paragraph

Article in Lung cancer (Amsterdam, Netherlands), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 58 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Feasibility of EBUS-TBNA for the molecular characterization of non-small cell lung cancer.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2024
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Simon R TurnerThoracic Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA.
Darren BuonocorePathology Services, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA.
Patrice DesmeulesPathology Services, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA.
Natasha RekhtmanPathology Services, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA.
Snjezana DoganPathology Services, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA.
Oscar LinPathology Services, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA.
Maria E ArcilaPathology Services, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA.
David R JonesThoracic Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA.
James HuangThoracic Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA. Electronic address: huangj@mskcc.org.
Memorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

introductionNext-generation sequencing (NGS) allows for the identification of a growing number of therapeutic and prognostic molecular targets. However, NGS typically requires greater quantities of DNA than traditional molecular testing does. Endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA) is a minimally invasive procedure used to sample central thoracic lesions, but it is not well established whether this technique provides sufficient material for NGS.

methodsWe performed a retrospective review of EBUS-TBNA at our institution (3/1/14-9/28/16). NGS was performed using a comprehensive hybrid-capture based assay (MSK-IMPACT) that detects >340 gene mutations. Samples found to be diagnostic for malignancy and for which MSK-IMPACT had been attempted were identified. Pathologic and clinical data were obtained from the medical record, and the results of MSK-IMPACT were examined.

resultsIn total, 784 EBUS-TBNA procedures were performed during the study period. MSK-IMPACT was requested for 115 malignant samples and was successful for 99 (86.1%), identifying an average of 12.7 mutations at a mean coverage depth of 806X. NGS was performed on paraffin-embedded cell blocks in 93 cases (93.9%) and on cell-free DNA in needle rinse fluid in 6 cases. The success rate of the assay improved significantly from the first third of cases (76.3%), to 92.3% for the final one-third of cases (p < 0.05).

conclusionsEBUS-TBNA reliably provided adequate tissue for hybrid capture NGS, and is a suitable option for comprehensive NGS testing in patients with thoracic malignancies.

Indexed as

BronchiDNA Mutational AnalysisElectronic Health RecordsEndoscopic Ultrasound-Guided Fine Needle AspirationFeasibility StudiesHigh-Throughput Nucleotide SequencingHumansMiniaturizationMinimally Invasive Surgical ProceduresMutationRetrospective StudiesThoracic NeoplasmsEndobronchial ultrasoundLung cancerMSK-IMPACTNext-generation sequencing

Identifiers

PMID29656758
PMCPMC5905717
OpenAlexW2793277866

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.